Biotech Valuation Framework

1. Start with the correct valuation language

2. Build the enterprise-value bridge

Begin with the latest reported share count and balance sheet, then adjust for material events after the quarter end. A useful bridge is:

Enterprise value ≈ equity value + debt and debt-like obligations − unrestricted cash and marketable securities.

The word “approximately” matters. Restricted cash may not fund operations. Convertible debt can behave partly like equity. Collaboration liabilities, preferred shares, milestone obligations and lease liabilities may require separate treatment. Do not mechanically subtract every dollar labeled cash or add every liability without understanding its economic role.

Post-quarter adjustments

• New share offerings, ATM sales or warrant exercises.
• Debt draws, repayments or conversions.
• Upfront collaboration payments or milestone receipts.
• Acquisitions, asset purchases or restructuring charges.
• Material cash burn since the reporting date.

3. Build revenue from patients, not from a round number

Peak sales should emerge from a patient funnel. Start with epidemiology and narrow the population step by step.

A simplified annual-revenue equation is:

Revenue = treated patients × product share × net price × treatment duration or annualization factor.

For chronic therapy, persistence and adherence matter. For one-time treatments, eligible incident patients, backlog conversion and treatment-center capacity may dominate. For oncology, line of therapy, biomarker testing, response duration and sequencing can change the model.

4. Price is not revenue per patient

Public list price is not the same as net realized price. Gross-to-net deductions may include rebates, discounts, government programs, distribution fees, patient assistance, returns and other adjustments. International pricing can be materially lower and launch timing differs by country.

Model separate geographies when possible. A product licensed outside the United States may generate royalties rather than direct revenue. A partner may control pricing, development or commercialization, which changes both economics and expenses.

Questions for the price assumption

• Is treatment chronic, episodic or one-time?
• What are credible analogs with similar severity and treatment setting?
• What monitoring, administration or hospitalization costs accompany therapy?
• Will payers require prior authorization, step therapy or outcomes evidence?
• What gross-to-net range is realistic at launch and at maturity?

5. Penetration and the revenue ramp

Peak share is not achieved on approval day. Adoption depends on physician awareness, guideline inclusion, reimbursement, diagnostic capacity, sales reach, manufacturing supply, patient willingness and competitor responses.

A good model includes annual patient and revenue ramps rather than jumping directly to peak sales. Time affects present value, financing needs and competitive risk. A one-year launch delay can materially reduce value even if the same theoretical peak is eventually reached.

6. Revenue is not free cash flow

Commercial value depends on economics after costs. Model cost of goods, royalties, milestones, sales and marketing, medical affairs, distribution, postmarketing studies, ongoing R&D, taxes and corporate overhead.

7. Risk adjustment: probability is an assumption, not a fact

Development-stage assets are commonly valued using probability-adjusted scenarios. The concept is simple:

Risk-adjusted value = probability of the outcome × present value if that outcome occurs.

The implementation is not simple. There is no single correct probability for every Phase 2 or Phase 3 asset. Probability should reflect trial design, endpoint validation, therapeutic area, modality, prior evidence, safety, CMC readiness, regulator feedback and competition. Historical averages may provide a reference point, but asset-specific evidence should drive the final assumption.

8. Risk-adjusted net present value

Risk-adjusted net present value, or rNPV, discounts future cash flows to today and weights development outcomes by probability. A simplified structure is:

Asset rNPV = present value of probability-weighted future cash flows − present value of probability-weighted remaining development costs.

A full model should represent time explicitly. Revenue expected six years from now is worth less today than revenue next year. Development costs occur before approval and may be paid even when the program ultimately fails. Probabilities may also change by stage rather than being applied as one constant factor to every cash flow.

Discount rate

The discount rate reflects time value and risk not otherwise captured. There is no universal biotech rate. Using a very high rate plus a low probability can again double-count risk. The model should explain why a rate was selected and test alternatives.

Terminal value and patent life

Do not assume perpetual growth for an asset facing patent expiry, biological competition or loss of exclusivity. Model the effective commercial life, patent estate, regulatory exclusivity, potential extensions and the erosion pattern after exclusivity ends.

9. Sum-of-the-parts valuation

Multi-asset companies are better analyzed as a sum of parts:

• Risk-adjusted value of each clinical asset.
• Value of approved products or royalties.
• Cash and marketable securities.
• Debt and other senior claims.
• Corporate overhead not captured at asset level.
• Near-term financing need.

Platform and preclinical programs may deserve optionality, but avoid assigning full stand-alone value to every discovery program. Shared mechanisms, correlated safety risks and competition can make pipeline outcomes less independent than a spreadsheet suggests.

10. Cash runway and burn

Runway determines whether the company can reach value-creating milestones without new capital. A starting approximation is:

Runway in quarters ≈ usable cash ÷ normalized quarterly cash burn.

Normalize the burn. One quarter may include an upfront milestone, restructuring payment or working-capital swing. Conversely, a company may be about to start an expensive pivotal study or commercial launch, making the historical burn too low.

Runway questions

• What portion of reported cash is unrestricted and available?
• What costs are committed but not yet visible in historical burn?
• Does management’s runway statement assume cost cuts, milestones or financing?
• How far beyond the next catalyst does cash extend?
• What minimum cash balance is required by debt covenants?

11. Dilution mechanics

Dilution is not simply “more shares.” The price, timing, attached securities and use of proceeds determine the economic effect. Read the actual SEC filings.

The fully diluted scenario should also include expected future financing when the current model cannot reach cash-flow breakeven. Leaving that financing out makes the company valuation and the per-share valuation inconsistent.

12. Partnership and royalty economics

A licensing deal can validate an asset and reduce funding needs, but headline “deal value” often includes distant contingent milestones that may never be earned.

Break the agreement into components

• Cash received upfront.
• Equity investment and its pricing.
• Development, regulatory and commercial milestones.
• Royalty range and whether it is tiered.
• Cost-sharing obligations.
• Territories and indications retained.
• Control of development and commercialization.
• Termination, opt-out and reversion provisions.

Value only the economics likely to accrue under each scenario. Do not add the maximum headline amount to valuation as if it were cash in the bank.

13. Commercial-stage valuation

Once a product launches, probability risk declines and execution data become more important. Useful measures may include net product revenue, sequential and year-over-year growth, new-patient starts, persistency, gross-to-net, gross margin, sales and marketing efficiency and the path to operating cash flow.

Revenue multiples can provide a rough market comparison, but only among businesses with similar growth, durability, margin, concentration and patent life. A fast-growing launch with long exclusivity is not comparable to a mature product facing competition merely because both are biotech companies.

14. Worked example: fictional late-stage biotech

Consider a fictional company, Asterion Therapeutics, developing a late-stage drug for a rare chronic disease.

Patient and price assumptions

• 8,000 diagnosed U.S. patients.
• 60% potentially eligible under the modeled label.
• 35% mature product penetration in the base case.
• $220,000 annual list price.
• 20% gross-to-net deduction.
• 90% average persistence over the modeled year.

The mature treated population would be approximately 1,680 patients before persistence adjustment: 8,000 × 60% × 35%. Applying net price of $176,000 and 90% persistence produces approximate U.S. mature annual revenue of $266 million. This is not yet asset value; it is one revenue scenario.

Economics and probability

Assume a 20% royalty on net sales, meaningful commercial costs and a seven-year ramp to peak. Remaining development and launch spending must be modeled before free cash flow. If the analyst assigns a 65% probability to the approval-and-launch scenario, that probability should be justified by the evidence and tested at lower and higher levels.

Cash and dilution

Asterion has $150 million of usable cash and normalized burn of $35 million per quarter, but the pivotal trial and prelaunch build are expected to accelerate spending. The company also has 50 million basic shares, 6 million options and restricted units, 8 million warrants and likely needs another $180 million before reaching sustainable commercial cash flow.

A valuation divided only by the current 50 million shares would overstate the base-case per-share outcome. The model should test an expected financing price and resulting new shares, while recognizing that the actual price will depend on future events.

The example shows why a transparent model is more useful than a fixed multiple. Every major conclusion can be traced to a patient, price, probability, time, cost or share-count assumption.

15. Sensitivity analysis and implied expectations

Because biotech assumptions are uncertain, a valuation should be presented as a range. Test the variables that drive the conclusion rather than changing every cell.

• Eligible patients and final label.
• Peak penetration and time to peak.
• Net price and gross-to-net.
• Probability of success.
• Launch delay and patent life.
• Royalty and margin.
• Future financing price and fully diluted shares.

Reverse valuation is equally useful: ask what probability, peak sales or market share the current enterprise value appears to imply. This identifies whether the market is pricing failure, moderate success or near-perfection without pretending the market’s assumptions are directly observable.

16. Biotech valuation checklist

17. Bottom line

Biotech valuation is strongest when every conclusion can be traced to an explicit assumption. Patient-based revenue, probability-adjusted cash flows and a transparent enterprise-value bridge expose where disagreement really lies. Including future financing and fully diluted shares prevents a good asset thesis from being mistaken for an equally good per-share outcome.

Chapter 5 completes the masterclass by turning the catalyst, evidence, regulatory and valuation work into a repeatable due-diligence framework of red flags, green flags and unresolved questions.